Crown Bioscience Enters Japanese Market via Strategic Partnership with Shin Nippon Biomedical Laboratories
April 24, 2014
The partnership is strategically important for Crown and marks another significant step in expanding its international footprint following the company’s recent expansion into Europe during which Crown acquired PRECOS Ltd in July 2013. SNBL has multiple facilities across Japan, the United States, China, and Cambodia and as such offers Crown access to a global target audience. While Crown is the world’s leading supplier of oncology services, with a global footprint spanning three major continents in North America, Europe and Asia Pacific, Japan is seen as a market with significant further potential. As a result of the partnership, both companies will also look at the potential to co-develop new models and services leveraging their respective expertise in Oncology/Diabetes and non-human primate model development.
Jean-Pierre Wery, President of Crown comments, “This strategic partnership offers Crown an excellent opportunity to develop a greater understanding of the Japanese market in order to further develop unique cutting-edge models. It is the first time that SNBL has agreed to represent an overseas company in such a deal. We are delighted to be partnering with the largest preclinical contract research organization in Japan as part of our international business strategy to develop our services in the Far East.”
Ryoichi Nagata, CEO and President of SNBL comments, “SNBL is committed to providing our customers with fast and precise results across the entire drug development spectrum, from early discovery research to late-stage clinical trials. This unique partnership with Crown will enable us to strengthen our service offering, and also to collaborate on a variety of pre-clinical projects, utilizing unique clinically relevant models, with a shared goal of improving patient care and treatment outcomes. Our expertise in preclinical development provides a perfect complement to Crown’s existing global services.”
Jean-Pierre Wery continues, “We are looking forward to working with SNBL to increase business opportunities with prospective customers across Japan and the Far East. Japan is one of the fastest growing pharmaceutical markets and there is great potential to help our clients working in the pharmaceutical and biotechnology industries to redefine translational research and establish ground-breaking therapeutics via our drug discovery solutions.”
For more information please email firstname.lastname@example.org, call 001 855 827 6968 or visitwww.crownbio.com
About Crown Bioscience Inc.
Founded in 2006, Crown Bioscience is a premier drug discovery and development service company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrials™ and HuSignature™ platforms enable unique lead optimization and translational strategies to deliver superior clinical candidates. Headquartered in Santa Clara California, Crown Bioscience has operations in China (Beijing and Jiangsu Taicang) and the USA (NC) with business offices in Boston, Princeton, RTP, Phoenix, Milan and Shanghai. For more information, please visithttp://www.crownbio.com
For further press information please contact: David Bertram – The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: email@example.com
About Shin Nippon Biomedical Laboratories:
For more than 55 years, SNBL has been a leader in providing development services to biopharmaceutical companies, generating high quality data with the exceptional precision needed to rapidly advance new medical therapies and innovations that improve patients’ lives.
In addition to providing services, SNBL has a Translational Research business, which utilizes its development capabilities to develop value-adding technologies and provides them to the pharmaceutical and medical industry. Under such business, SNBL has developed μco™ System, a novel intranasal drug delivery technology platform, to provide effective delivery solutions to pharmaceutical products.